Global Isosorbide Mononitrate Market Size By Type (10 mg Tablet, 20 mg Tablet), By Application (Treatment of Angina Pectoris, Others), By Region, And Segment Forecasts, 2023 to 2032

lobal Isosorbide Mononitrate Market Report Description

The Global Isosorbide Mononitrate Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.4 billion by 2031, growing at a CAGR of 7.9% during the forecast period of 2023–2031. Isosorbide mononitrate, a nitrate-class drug, is primarily used for the prevention and long-term treatment of angina pectoris and heart failure. The market is expanding due to the increasing prevalence of cardiovascular diseases (CVDs), especially in aging populations, and rising awareness regarding preventive cardiac healthcare. Furthermore, advancements in drug delivery systems and expanding access to healthcare in emerging economies are fueling demand.

Drivers:

1. Rising Cardiovascular Disease Burden:

Globally, CVDs are the leading cause of mortality. The demand for effective anti-anginal medications such as isosorbide mononitrate is growing in parallel with this trend, especially among older adults.

2. Aging Global Population:

With the increasing number of elderly individuals worldwide—particularly in Europe, North America, and parts of Asia—the prevalence of chronic heart conditions requiring long-term vasodilator therapy is rising.

3. Improved Access to Healthcare:

Emerging markets are witnessing improved access to healthcare services and essential medications, which is contributing to greater prescription rates of isosorbide mononitrate.

Restraints:

1. Side Effects and Contraindications:

Common side effects such as headaches, hypotension, and tolerance development may limit long-term patient adherence. These clinical drawbacks can reduce the drug’s appeal compared to alternative therapies.

2. Patent Expiry and Generic Competition:

Several formulations of isosorbide mononitrate have become available as generics, increasing price competition and compressing profit margins for branded drug manufacturers.

Opportunity:

1. Expansion into Emerging Markets:

Rising healthcare infrastructure investments and public health initiatives in Asia-Pacific, Africa, and Latin America offer significant opportunities for market expansion.

2. Development of Extended-Release Formulations:

Innovations in drug formulation technologies, particularly controlled and extended-release tablets, are creating new product opportunities for companies targeting patient convenience and compliance.

Market by System Type Insights:

The Oral Extended-Release Tablets segment accounted for the largest market share in 2023. These formulations offer better patient compliance by minimizing dosing frequency and reducing peak-trough fluctuations in plasma concentration. Meanwhile, the Immediate-Release Tablets segment is also widely prescribed for acute symptom management and is expected to experience stable growth.

Market by End-use Insights:

The Hospitals segment was the largest end-use category in 2023, driven by the need for rapid diagnosis and treatment initiation for cardiovascular events. However, the Retail Pharmacies segment is growing rapidly, supported by an increase in outpatient prescriptions and home-based chronic care models.

Market by Regional Insights:

North America dominated the global market in 2023, owing to a high incidence of heart-related diseases, advanced healthcare infrastructure, and early adoption of extended-release drugs. However, the Asia-Pacific region is forecast to exhibit the highest growth rate, fueled by urbanization, changing lifestyles, and increasing healthcare expenditure in countries like India and China.

Competitive Scenario:

Major players in the global isosorbide mononitrate market include Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Ltd., Aurobindo Pharma, Taj Pharmaceuticals Ltd., and Lupin Limited. Companies are focusing on expanding their generic product portfolios, investing in controlled-release technologies, and enhancing global distribution networks.

Scope of Work – Global Isosorbide Mononitrate Market

Key Market Developments:

2023: Teva Pharmaceuticals launched a new line of extended-release isosorbide mononitrate tablets in several European countries.

2024: Sun Pharma expanded its cardiac therapeutic segment in Latin America, emphasizing nitrate-based formulations.

2025: Lupin Limited initiated clinical trials for a dual-action nitrate formulation combining isosorbide mononitrate and a beta-blocker.

FAQs:

1) What is the current market size of the Global Isosorbide Mononitrate Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Isosorbide Mononitrate Market?

The major growth driver is the rising prevalence of cardiovascular diseases worldwide.

3) Which is the largest region during the forecast period in the Global Isosorbide Mononitrate Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow fastest.

4) Which segment accounted for the largest market share in the Global Isosorbide Mononitrate Market?

The Oral Extended-Release Tablets segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Isosorbide Mononitrate Market?

Key players include Merck KGaA, Teva, Sun Pharma, Mylan, Zydus, Aurobindo, Taj Pharma, and Lupin Limited.

Let me know if you want this formatted into a downloadable document or tailored further.